Tags

Type your tag names separated by a space and hit enter

Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies.
Medicine (Baltimore) 2017; 96(45):e8613M

Abstract

Lower serum level of 25-hydroxyvitamin D is associated with several negative outcomes. However, previous studies have indicated that 25-hydroxyvitamin D is associated with lung cancer risk and survival, but presented controversial results.PubMed and Embase databases were searched update to August 2017 to identify and quantify the potential association between 25-hydroxyvitamin D and lung cancer risk and survival.Seventeen eligible studies involving a total of 138,858 participants with 4368 incident cases were included in this meta-analysis. Our results showed statistically significant association between 25-hydroxyvitamin D and lung cancer risk and mortality. However, circulating 25-hydroxyvitamin D was not associated with overall lung cancer survival. Furthermore, compared with the lowest circulating 25-hydroxyvitamin D, the highest circulating 25-hydroxyvitamin D is significantly decreased risk of lung cancer risk in male and female. In addition, the highest circulating 25-hydroxyvitamin D was significantly associated with a lower risk in Caucasian and Asian. We also obtained the best fit at an inflection point of 10 nmol/L in piecewise regression analysis, increasing 10 nmol/L dose of circulating 25-hydroxyvitamin D was associated with an 8% reduction in the risk of lung cancer risk and an 7% reduction in the risk of lung cancer mortality. Subgroup meta-analyses in study quality, number of participants, and number of cases showed consistent with the primary findings.The highest circulating 25-hydroxyvitamin D was associated with decreased lung cancer risk and mortality but not overall survival.

Authors+Show Affiliations

Department of Respiratory Medicine, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

29137092

Citation

Feng, Qianqian, et al. "Circulating 25-hydroxyvitamin D and Lung Cancer Risk and Survival: a Dose-response Meta-analysis of Prospective Cohort Studies." Medicine, vol. 96, no. 45, 2017, pp. e8613.
Feng Q, Zhang H, Dong Z, et al. Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017;96(45):e8613.
Feng, Q., Zhang, H., Dong, Z., Zhou, Y., & Ma, J. (2017). Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. Medicine, 96(45), pp. e8613. doi:10.1097/MD.0000000000008613.
Feng Q, et al. Circulating 25-hydroxyvitamin D and Lung Cancer Risk and Survival: a Dose-response Meta-analysis of Prospective Cohort Studies. Medicine (Baltimore). 2017;96(45):e8613. PubMed PMID: 29137092.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. AU - Feng,Qianqian, AU - Zhang,Han, AU - Dong,Zhengqin, AU - Zhou,Yang, AU - Ma,Jingping, PY - 2017/11/16/entrez PY - 2017/11/16/pubmed PY - 2017/11/29/medline SP - e8613 EP - e8613 JF - Medicine JO - Medicine (Baltimore) VL - 96 IS - 45 N2 - Lower serum level of 25-hydroxyvitamin D is associated with several negative outcomes. However, previous studies have indicated that 25-hydroxyvitamin D is associated with lung cancer risk and survival, but presented controversial results.PubMed and Embase databases were searched update to August 2017 to identify and quantify the potential association between 25-hydroxyvitamin D and lung cancer risk and survival.Seventeen eligible studies involving a total of 138,858 participants with 4368 incident cases were included in this meta-analysis. Our results showed statistically significant association between 25-hydroxyvitamin D and lung cancer risk and mortality. However, circulating 25-hydroxyvitamin D was not associated with overall lung cancer survival. Furthermore, compared with the lowest circulating 25-hydroxyvitamin D, the highest circulating 25-hydroxyvitamin D is significantly decreased risk of lung cancer risk in male and female. In addition, the highest circulating 25-hydroxyvitamin D was significantly associated with a lower risk in Caucasian and Asian. We also obtained the best fit at an inflection point of 10 nmol/L in piecewise regression analysis, increasing 10 nmol/L dose of circulating 25-hydroxyvitamin D was associated with an 8% reduction in the risk of lung cancer risk and an 7% reduction in the risk of lung cancer mortality. Subgroup meta-analyses in study quality, number of participants, and number of cases showed consistent with the primary findings.The highest circulating 25-hydroxyvitamin D was associated with decreased lung cancer risk and mortality but not overall survival. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/29137092/Circulating_25_hydroxyvitamin_D_and_lung_cancer_risk_and_survival:_A_dose_response_meta_analysis_of_prospective_cohort_studies_ L2 - http://dx.doi.org/10.1097/MD.0000000000008613 DB - PRIME DP - Unbound Medicine ER -